MRNA
Moderna Inc.Stock · HealthcareS&P 500 Equal Weight 0.2% · Nasdaq Composite 0.04% · S&P 500 0.04% · Russell 1000 0.04% · Russell 3000 0.04% · US Stock Market 0.03%$143.97+5.38%
as of market close, Sep 11, 2026
☾ AH $144.48 +0.35%
MRNA financial statements
The full income statement, balance sheet, and cash-flow statement for Moderna Inc. (MRNA), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 384.4M2024-09 384.8M2024-12 385.8M2025-03 386.7M2025-06 389.1M2025-09 390.7M2025-12 394.9M2026-03 396.8M2026-06 399.2M+3.9% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 1.94B-39.9% | 3.24B-52.7% | 6.85B-64.4% | 19.3B+4.3% | 18.5B+2200.2% | |
| Cost of revenue | 868M-40.7% | 1.46B-68.8% | 4.69B-13.3% | 5.42B+107.0% | 2.62B+32612.5% | |
| Research & development | 3.13B-31.1% | 4.54B-6.2% | 4.84B+47.0% | 3.29B+65.5% | 1.99B+45.3% | |
| Selling, general & administrative | 1.02B-13.3% | 1.17B-24.2% | 1.55B+36.8% | 1.13B+99.6% | 567M+201.6% | |
| General & administrative | 1.02B-13.3% | 1.17B-24.2% | 1.55B+36.8% | 1.13B+99.6% | 567M+201.6% | |
| Provision for credit losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating income | -3.07B+22.1% | -3.94B+6.9% | -4.24B-145.0% | 9.42B-29.2% | 13.3B+1842.6% | |
| Interest & investment income | 314M-26.1% | 425M+1.0% | 421M+110.5% | 200M+1011.1% | 18.0M-28.0% | |
| Other non-operating income | -8.00M+90.8% | -87.0M+29.8% | -124M-175.6% | -45.0M-55.2% | -29.0M-383.3% | |
| Pre-tax income | -2.77B+23.3% | -3.61B+8.5% | -3.94B-141.2% | 9.57B-27.9% | 13.3B+1885.6% | |
| Income tax | 54.0M+217.4% | -46.0M-106.0% | 772M-36.4% | 1.21B+12.0% | 1.08B+36000.0% | |
| Net income | -2.82B+20.8% | -3.56B+24.5% | -4.71B-156.4% | 8.36B-31.5% | 12.2B+1733.5% | |
| -$7.26+21.8% | -$9.28+24.7% | -$12.33-161.3% | $20.12-28.9% | $28.29+1543.4% | ||
| EPS (basic) | -$7.26+21.8% | -$9.28+24.7% | -$12.33-158.0% | $21.26-29.9% | $30.31+1646.4% | |
| Weighted-avg shares (basic) | 389M+1.3% | 384M+0.5% | 382M-3.0% | 394M-2.2% | 403M+5.8% | |
| Weighted-avg shares (diluted) | 389M+1.3% | 384M+0.5% | 382M-8.2% | 416M-3.5% | 431M+13.1% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 6.54B-19.2% | 8.10B-21.6% | 10.3B-23.1% | 13.4B-16.4% | 16.1B+155.2% | ||
| Cash & equivalents | 2.60B+34.7% | 1.93B-33.7% | 2.91B-9.3% | 3.21B-53.2% | 6.85B+161.0% | |
| Accounts receivable | 184M-48.6% | 358M-59.9% | 892M-35.6% | 1.39B-56.4% | 3.17B+128.3% | |
| Inventory | 153M+30.8% | 117M-42.1% | 202M-78.7% | 949M-34.1% | 1.44B+2966.0% | |
| Prepaid expenses | 408M-31.9% | 599M-4.5% | 627M-47.5% | 1.20B+64.1% | 728M+188.9% | |
| Other current assets | 45.0M-22.4% | 58.0M-34.1% | 88.0M+100.0% | 44.0M+69.2% | 26.0M+136.4% | |
| 12.3B-12.8% | 14.1B-23.2% | 18.4B-28.7% | 25.9B+4.8% | 24.7B+236.2% | ||
| Operating lease right-of-use | 719M-5.3% | 759M+6.5% | 713M+489.3% | 121M-14.8% | 142M+57.8% | |
| Goodwill | 52.0M+0.0% | 52.0M+0.0% | 52.0M | 0.00 | — | |
| Intangible assets | 45.0M+12.5% | 40.0M-9.1% | 44.0M | 0.00 | — | |
| Deferred tax assets | 81.0M+0.0% | 81.0M+0.0% | 81.0M-91.8% | 982M+201.2% | 326M | |
| Other non-current assets | 605M+1.9% | 594M-22.5% | 766M-22.5% | 988M+2047.8% | 46.0M+2200.0% | |
| 1.99B-9.9% | 2.21B-26.8% | 3.02B-38.8% | 4.92B-46.1% | 9.13B+108.0% | ||
| Accounts payable | 317M-21.7% | 405M-22.1% | 520M+6.8% | 487M+61.3% | 302M+1577.8% | |
| Accrued liabilities | 1.39B-2.9% | 1.43B-20.6% | 1.80B-14.4% | 2.10B+42.7% | 1.47B+213.2% | |
| Deferred revenue | 99.0M-35.3% | 153M-73.1% | 568M-72.1% | 2.04B-67.4% | 6.25B+61.7% | |
| Current lease liability | 17.0M+21.4% | 14.0M-44.0% | 25.0M-28.6% | 35.0M-23.9% | 46.0M+666.7% | |
| Other current liabilities | 185M-16.3% | 221M+71.3% | 129M-48.2% | 249M+10.7% | 225M+561.8% | |
| Finance lease liability (current) | 25.0M+8.7% | 23.0M | 0.00-100.0% | 161M-2.4% | 165M+587.5% | |
| 3.69B+13.8% | 3.24B-29.1% | 4.57B-32.1% | 6.74B-36.0% | 10.5B+120.4% | ||
| Long-term debt | 590M | 0.00 | — | — | — | |
| Deferred revenue (non-current) | 153M+163.8% | 58.0M-30.1% | 83.0M-87.7% | 673M+9.4% | 615M+247.5% | |
| Non-current lease liability | 653M-2.7% | 671M+4.4% | 643M+598.9% | 92.0M-13.2% | 106M+9.3% | |
| Operating lease liability (total) | 670M-2.2% | 685M+2.5% | 668M+426.0% | 127M-16.4% | 152M+47.0% | |
| Finance lease liability (total) | 45.0M-27.4% | 62.0M-89.2% | 575M-46.4% | 1.07B+40.4% | 764M+469.3% | |
| Finance lease liability | 20.0M-48.7% | 39.0M-93.2% | 575M-37.0% | 912M+52.3% | 599M+444.5% | |
| Deferred tax liabilities | 249M+7.8% | 231M-1.7% | 235M | — | — | |
| Other non-current liabilities | 285M+6.7% | 267M+4.3% | 256M+89.6% | 135M+77.6% | 76.0M+2433.3% | |
| 8.65B-20.6% | 10.9B-21.3% | 13.9B-27.6% | 19.1B+35.2% | 14.1B+452.3% | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Additional paid-in capital | 1.38B+59.6% | 866M+133.4% | 371M-68.4% | 1.17B-72.1% | 4.21B-12.3% | |
| Retained earnings | 7.22B-28.1% | 10.0B-26.2% | 13.6B-25.7% | 18.3B+84.0% | 9.96B+543.8% | |
| Accumulated other comprehensive income | 45.0M+550.0% | -10.0M+91.9% | -123M+66.8% | -370M-1441.7% | -24.0M-900.0% | |
| Total liabilities & equity | 12.3B-12.8% | 14.1B-23.2% | 18.4B-28.7% | 25.9B+4.8% | 24.7B+236.2% | |
| Common shares issued | 394M+2.1% | 386M+1.0% | 382M-0.8% | 385M-4.5% | 403M+1.0% | |
| Common shares outstanding | 394M+2.1% | 386M+1.0% | 382M-0.8% | 385M-4.5% | 403M+1.0% | |
| Shares outstanding (cover) | 395M+2.4% | 386M+1.0% | 382M-1.1% | 386M-4.1% | 403M+0.8% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| -1.87B+37.6% | -3.00B+3.7% | -3.12B-162.6% | 4.98B-63.4% | 13.6B+571.9% | ||
| Depreciation & amortization | 211M+14.1% | 185M-70.0% | 617M+77.3% | 348M+50.0% | 232M+648.4% | |
| Share-based compensation | 483M+12.6% | 429M+40.7% | 305M+35.0% | 226M+59.2% | 142M+52.7% | |
| Deferred income taxes | 10.0M+1100.0% | -1.00M-100.1% | 901M+255.9% | -578M-95.3% | -296M | |
| Change in receivables | -156M+70.8% | -534M-8.3% | -493M+72.5% | -1.79B-200.3% | 1.78B+28.8% | |
| Change in inventory | 34.0M+141.0% | -83.0M+88.9% | -747M-51.8% | -492M-135.3% | 1.39B+2866.0% | |
| Change in payables | -92.0M-33.3% | -69.0M-630.8% | 13.0M-94.6% | 240M+17.6% | 204M+1600.0% | |
| 1.95B-0.2% | 1.95B-53.7% | 4.21B+181.3% | -5.18B+39.3% | -8.52B-409.7% | ||
| Capital expenditure | 192M-81.7% | 1.05B+48.7% | 707M+76.8% | 400M+40.8% | 284M+317.6% | |
| Free cash flow | -2.06B+49.1% | -4.05B-6.0% | -3.83B-183.5% | 4.58B-65.6% | 13.3B+580.8% | |
| Acquisitions | 0.00 | 0.00-100.0% | 85.0M | 0.00 | 0.00 | |
| Sales/maturities of investments | 5.56B+0.0% | 5.56B-0.2% | 5.58B+76.9% | 3.15B+135.5% | 1.34B+17.7% | |
| 593M+958.9% | 56.0M+104.1% | -1.38B+60.1% | -3.45B-295.0% | -873M-142.9% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | |
| Common stock repurchased | 2.00M | 0.00-100.0% | 1.15B-65.4% | 3.33B+288.4% | 857M | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net change in cash | 668M+166.9% | -999M-245.7% | -289M+92.1% | -3.64B-186.2% | 4.22B+76.9% | |
| Interest paid | 10.0M-58.3% | 24.0M-38.5% | 39.0M+56.0% | 25.0M+78.6% | 14.0M+55.6% | |
| Income taxes paid | 26.0M-86.8% | 197M+155.2% | -357M-113.1% | 2.73B+468.5% | 480M+47900.0% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 11.6B-27.4% | 16.0B-57.7% | 37.9B-45.1% | 69.0B-32.6% | 102B+145.0% | |
| P/E | — | — | — | 5.9×-30.1% | 8.4× | |
| P/S | 6.0×+20.9% | 5.0×+19.2% | 4.2×+28.9% | 3.2×-41.8% | 5.5×-89.3% | |
| P/B | 1.3×-8.5% | 1.5×-47.8% | 2.8×-26.5% | 3.8×-47.0% | 7.2×-55.6% | |
| P/FCF | — | — | — | 11.1×+45.0% | 7.7×-64.0% | |
| Earnings yield | — | — | — | 17.0%+43.0% | 11.9% | |
| FCF yield | — | — | — | 9.0%-31.1% | 13.0%+177.9% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: MRNA’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all MRNA filings on SEC EDGAR → Not investment advice.